CN113491337A - Composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof - Google Patents
Composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof Download PDFInfo
- Publication number
- CN113491337A CN113491337A CN202110665006.0A CN202110665006A CN113491337A CN 113491337 A CN113491337 A CN 113491337A CN 202110665006 A CN202110665006 A CN 202110665006A CN 113491337 A CN113491337 A CN 113491337A
- Authority
- CN
- China
- Prior art keywords
- chain fatty
- metabolism
- intestinal
- composition
- fatty acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000004666 short chain fatty acids Chemical class 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 21
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims description 30
- 230000004129 fatty acid metabolism Effects 0.000 title claims description 5
- 235000021391 short chain fatty acids Nutrition 0.000 claims abstract description 40
- 230000000968 intestinal effect Effects 0.000 claims abstract description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 33
- 230000004060 metabolic process Effects 0.000 claims abstract description 25
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 23
- 241001465754 Metazoa Species 0.000 claims abstract description 20
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 20
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 19
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 14
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 14
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 14
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 14
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 7
- 235000013336 milk Nutrition 0.000 claims description 8
- 239000008267 milk Substances 0.000 claims description 8
- 210000004080 milk Anatomy 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000000936 intestine Anatomy 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims 2
- 239000002417 nutraceutical Substances 0.000 claims 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims 2
- 235000020122 reconstituted milk Nutrition 0.000 claims 2
- 241001134770 Bifidobacterium animalis Species 0.000 abstract description 9
- 229940118852 bifidobacterium animalis Drugs 0.000 abstract description 9
- 230000006870 function Effects 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 238000013329 compounding Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010088847 Peptide YY Proteins 0.000 description 1
- 102100029909 Peptide YY Human genes 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940108924 conjugated linoleic acid Drugs 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052603 melanterite Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a composition for regulating the metabolism of infant intestinal short-chain fatty acid, which comprises the following components: 3-6 parts of lactoferrin, 0.3-1 part of animal bifidobacterium powder and 40-60 parts of galacto-oligosaccharide; the animal bifidobacterium powder contains animal bifidobacterium 107~108CFU/part by weight. The composition disclosed by the invention can increase the total content of infant intestinal short-chain fatty acids and the content of acetic acid by compounding lactoferrin, bifidobacterium animalis and galactooligosaccharides, is beneficial to adjusting the metabolism of the infant intestinal short-chain fatty acids, and can be applied to preparation of medicines or foods with the functions of adjusting the metabolism of the infant intestinal short-chain fatty acids, increasing the content of the intestinal short-chain fatty acids or increasing the content of the intestinal acetic acid.
Description
Technical Field
The invention relates to the field of food, and in particular relates to a composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof.
Background
The intestinal flora coexists with the body and exerts a great deal of influence on the body in the aspects of metabolism, development and maturation of immune function, protection of intestinal tract and the like. The effects on the metabolism of the body, such as the production of short-chain fatty acids, mainly acetate, propionate and butyrate, can provide energy and maintain the growth and development of the gastrointestinal tract, and are very important for the intestinal health of infants. Some intestinal flora may synthesize vitamins, such as vitamin K and other vitamin B groups, that have important effects on infants. Some bacteria in the intestinal tract can also produce conjugated linoleic acid, which plays an important role in the normal growth and development of newborns, and is associated with obesity, diabetes and immune function. The gut flora may also influence the blood concentration of tryptophan, an essential amino acid, by the kynurenine pathway, which is important in the development of the central nervous system. The interaction between the intestine and the brain forms a brain-intestine axis, and integrates the mechanisms of nerve, immunity and endocrine, while the intestinal flora can play a role similar to signal molecules in the brain-intestine axis and play a role in regulating various aspects such as immune function, central nervous system and gastrointestinal function in the early life. The intestinal flora can influence the colonization and reproduction of pathogenic bacteria through biological antagonism, thereby protecting organisms from being damaged by the pathogenic bacteria. The intestinal bacteria have regulating effect on both innate immunity and adaptive immunity. Through aseptic animal experimental studies, it has been demonstrated that intestinal microorganisms are essential for maintaining normal intestinal morphology and immune maturation, and mice that survive aseptic conditions exhibit impaired development of the intestinal immune system and a defect in oral immune tolerance. Bifidobacteria in the recombinant gut flora may restore the oral tolerance during neonatal period.
Intestinal microorganisms are an important part of the human body and play a very important role in the development, function and regulation of the human immune system in various ways from birth. The evolutionary symbiotic relationship between humans and intestinal microorganisms has numerous benefits to humans, including regulation of host immunity, production of vitamin K and vitamin B, protection of the gut from pathogens, enhancement of gut integrity, and production of Short Chain Fatty Acids (SCFAs), metabolites. Short chain fatty acids are produced by intestinal flora by fermenting carbohydrates, mainly acetic acid, propionic acid, butyric acid, etc. Short Chain Fatty Acids (SCFA) mediate the interaction between gut flora and host metabolism, and the effects of both prebiotics and probiotics depend on SCFA. Short chain fatty acids are thought to mediate communication between the gut flora and the immune system, inhibiting the proliferation of certain bacteria by lowering the pH of the gut, and are critical to gut homeostasis. SCFAs can conduct signals through G protein sensitive G protein coupled receptors, and SCFAs circulating in blood can affect tissue specific acetylation of histones 3 and 4, and induce epigenetic change of genome; the content of SCFAs in intestinal tracts is increased through special diet, so that the diabetes of non-obese diabetic mice can be prevented; during pregnancy, SCFAs can cause epigenetic imprints in the uterus and prevent allergic diseases in the infant's airways; SCFAs also regulate blood brain barrier and neuroimmune endocrine function. Short chain fatty acids can inhibit Histone Deacetylases (HDACs), which are involved in regulating gene expression in many diseases and promoting the onset of disease. SCFAs play a beneficial role in the metabolism and function of adipose tissue, skeletal muscle and liver stroma and contribute to improved insulin sensitivity.
Acetate, propionate, butyrate are the major SCFAs, and lactate, succinate are precursors of SCFAs, produced mediated by specific intestinal microbial enzymes, at concentrations that are highest in the cecum and proximal colon, and are a source of colonic cellular energy. Animal and human data suggest that acetate affects host energy and substrate metabolism by regulating intestinal hormone secretion and metabolism substrates such as glucagon-like peptide-1 and peptide YY. Appetite is affected by reducing systemic lipolysis, levels of systemic inflammatory cytokines, increasing energy expenditure and fat oxidation. Acetate may also be produced by deacetylation of endogenous proteins, such as histones. Acetate plays a key role in maintaining intracellular levels of acetyl-coa, and disturbances in acetate metabolism are associated with several human diseases. Short Chain Fatty Acid (SCFA) produced by fermenting dietary fiber by intestinal flora has immunoregulation function.
There is currently no study on compositions that increase the content of short chain fatty acids in the infant's intestinal tract.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provide a composition for regulating the metabolism of short-chain fatty acids in the intestinal tract of infants and application thereof.
In order to achieve the purpose, the invention adopts the technical scheme that: a composition for regulating the metabolism of short chain fatty acids in the infant's intestinal tract, comprising the following components: 3-6 parts of lactoferrin, 0.3-1 part of animal bifidobacterium powder and 40-60 parts of galacto-oligosaccharide; the animal bifidobacterium powder contains animal bifidobacterium 107~108CFU/part by weight.
The inventor finds that the composition disclosed by the invention can increase the total content of infant intestinal short-chain fatty acids and the content of acetic acid by compounding lactoferrin, bifidobacterium animalis and galactooligosaccharides, and is beneficial to regulating the metabolism of the infant intestinal short-chain fatty acids.
Preferably, the composition comprises the following components: 5.5 parts by weight of lactoferrin, 0.5 part by weight of animal bifidobacterium powder and 50 parts by weight of galacto-oligosaccharide; the animal bifidobacterium powder contains animal bifidobacterium 107~108CFU/part by weight. The effect of increasing the total content of short chain fatty acid and the content of acetic acid in the intestinal tract of the infant by matching the three components in the proportion is better than that of two or one of the three components.
The invention also aims to provide the application of the composition for regulating the metabolism of the infant intestinal short-chain fatty acid in preparing a medicament or food with the function of regulating the metabolism of the infant intestinal short-chain fatty acid; preferably, the food is prepared milk powder, health-care products or drinks.
The invention also aims to provide application of the composition for regulating the intestinal short-chain fatty acid metabolism of infants in preparing medicines or foods with the function of increasing the intestinal short-chain fatty acid content or increasing the intestinal acetic acid content. Preferably, the food is prepared milk powder, health-care products or drinks.
The invention also aims to provide the modified milk powder, which comprises the composition for regulating the metabolism of the short-chain fatty acid in the intestinal tract of the infant.
Preferably, the weight percentage of the composition for regulating the metabolism of the infant intestinal short-chain fatty acid in the modified milk powder is 3-6%. When the composition is added into prepared milk powder, the metabolism of short-chain fatty acids in the intestinal tract of infants can be effectively regulated, and the intestinal health is maintained.
The invention has the beneficial effects that: the composition is prepared by compounding lactoferrin, animal bifidobacteria and galactooligosaccharides, can increase the total content of short-chain fatty acids and the content of acetic acid in the intestinal tract of infants, is favorable for adjusting the metabolism of the short-chain fatty acids in the intestinal tract of infants, and can be applied to preparation of medicines or foods with the functions of adjusting the metabolism of the short-chain fatty acids in the intestinal tract of infants, increasing the content of the short-chain fatty acids in the intestinal tract or increasing the content of the acetic acid in the intestinal tract.
Drawings
FIG. 1 is a graph showing the acetate content in a sample;
FIG. 2 is a graph showing the total short chain fatty acid content in the samples.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to specific examples.
The sources of the raw materials are as follows:
galacto-oligosaccharide: DP2-DP8, available from Quantum Kogaku;
lactoferrin: purchased from warranwood warenburg;
animal bifidobacterium powder: BB12 from Kehansen.
10 infants of 0-6 months are recruited in a company, the information such as the diet condition of the infants, the using condition of probiotics and the like is investigated, and 4 volunteers meeting the experimental requirements are selected from the information: feeding with pure breast milk, adding no supplementary food, preventing diarrhea or constipation in one month, and collecting feces samples after filling informed consent without using probiotics, medicine and antibiotics.
Three test groups were set:
1. galacto-oligosaccharides (GOS) group: 50mg of galacto-oligosaccharide;
2. lactoferrin + bifidobacterium animalis (LF + BB12) group: 5.5Lactoferrin and 0.5mg Bifidobacterium animalis powder (containing Bifidobacterium animalis 10. mu.m. in it)7CFU);
3. Lactoferrin + bifidobacterium animalis + galactooligosaccharides (LF + BB12+ GOS) group: 5.5mg of lactoferrin, 0.5mg of animal bifidobacterium powder (containing about bifidobacterium animalis 10 therein)7CFU) and 50mg galacto-oligosaccharide.
Preparing a trace element solution: scale FeSO4·7H2O 3.68g、MnSO4·H2O 1.159g、ZnSO4·7H2O 0.44g、CoCl2·6H2O 0.12g、NiCl2 0.10g、CuSO4·5H2O0.098 g and Mo7(CH4)6O24H2O0.017 g, dissolved in 1L of sterile water.
Preparing a buffer solution: MgCl2·6H2O 0.1g、NaSO4 0.1g、CaCl2·2H20.728g of O, 0.4g of urea, 0.45g of KCl, 0.47g of NaCl and Na2HPO4 2.824g、NaHCO39.24g of the mixture, 0.001mg of the Resazurin and 10ml of the trace element solution are mixed, the volume is determined to be 1L, and the mixture is sterilized for later use.
The excrement sample is tested one by one, firstly, the excrement sample is filtered, and the prepared buffer solution and the sample are added: buffer 1: 4, preparing the excrement homogenate. Taking 1ml of excrement homogenate to be filled into fermentation vials containing different raw materials, adding 3ml of buffer solution, covering the caps, and then carrying out anaerobic fermentation at 37 ℃. During the fermentation, the amount of short chain fatty acid was measured by gas phase at 4h, 8h,24h, and 48h, and the test results are shown in tables 1 and 2 and fig. 1 and 2.
TABLE 1 acetate content in the samples (unit: mmol/L)
Time | GOS | LF+BB12 | LF+BB12+ |
4h | 15.29±12.95 | 7.25±3.90 | 31.09±15.85 |
8h | 35.19±30.25 | 9.55±4.12 | 52.66±34.70 |
24h | 51.14±24.33 | 15.95±3.56 | 76.68±31.73 |
48h | 51.66±22.25 | 27.27±11.47 | 85.84±19.73 |
TABLE 2 Total short chain fatty acid content (unit: mmol/L) in the samples
Time | GOS | LF+BB12 | LF+BB12+ |
4h | 16.20±13.11 | 7.56±4.10 | 29.12±13.15 |
8h | 36.23±1.840 | 10.84±4.38 | 60.06±2.291 |
24h | 51.43±2.674 | 19.71±4.50 | 80.23±3.120 |
48h | 57.72±1.569 | 33.69±13.48 | 92.42±1.469 |
From tables 1 and 2 and fig. 1 and 2, it can be seen that the addition of GOS significantly increased the level of intestinal acetic acid over time by fermentation with the intestinal flora of pure breast-fed infants. The lactoferrin + bifidobacterium animalis + galacto-oligosaccharides (LF + BB12+ GOS) group started at 8h and produced higher total short chain fatty acids than the GOS group and LF + BB12 group, and than the sum of the other two groups, with significant differences, and also significantly higher at 24h and 48h than the other groups. Therefore, the composition can improve the generation amount of total short-chain fatty acid in the in-vitro simulated fermentation process, and can balance the content of key fatty acid metabolites such as acetic acid, propionic acid and butyric acid in the intestinal tracts of infants. Short chain fatty acids can lower the pH of the intestinal tract to inhibit proliferation of certain bacteria; the acetate has anticancer effect and can improve intestinal function. It can therefore be assumed that a composition comprising lactoferrin, galactooligosaccharides and bifidobacterium animalis is beneficial for healthy development of the infant's gut.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (8)
1. A composition for regulating the metabolism of short chain fatty acids in the infant's intestinal tract, comprising the following components: 3-6 parts of lactoferrin, 0.3-1 part of animal bifidobacterium powder and 40-60 parts of galacto-oligosaccharide; the animal bifidobacterium powder contains animal bifidobacterium 107~108CFU/part by weight.
2. The composition for modulating the metabolism of infant intestinal short chain fatty acids according to claim 1, wherein the composition comprises the following components: 5.5 parts by weight of lactoferrin, 0.5 part by weight of animal bifidobacterium powder and 50 parts by weight of galacto-oligosaccharide; the animal bifidobacterium powder contains animal bifidobacterium 107~108CFU/part by weight.
3. Use of the composition for regulating the metabolism of infant intestinal short-chain fatty acids according to claim 1 or 2 for preparing a medicament or food with the function of regulating the metabolism of infant intestinal short-chain fatty acids.
4. The use according to claim 3, wherein the food product is a reconstituted milk powder, a nutraceutical or a beverage product.
5. Use of a composition for modulating the intestinal short chain fatty acid metabolism in infants and young children according to claim 1 or 2 for the manufacture of a medicament or food product having an increased intestinal short chain fatty acid content or an increased intestinal acetic acid content.
6. The use of claim 5, wherein the food product is a reconstituted milk powder, a nutraceutical, or a beverage product.
7. Modified milk powder comprising a composition for modulating the metabolism of short chain fatty acids in the infant's intestine according to claim 1 or 2.
8. The modified milk powder of claim 7, wherein the composition for regulating the metabolism of infant intestinal short chain fatty acids is present in the modified milk powder in an amount of 3 to 6% by weight.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110665006.0A CN113491337A (en) | 2021-06-15 | 2021-06-15 | Composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110665006.0A CN113491337A (en) | 2021-06-15 | 2021-06-15 | Composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113491337A true CN113491337A (en) | 2021-10-12 |
Family
ID=77997616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110665006.0A Pending CN113491337A (en) | 2021-06-15 | 2021-06-15 | Composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113491337A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115989836A (en) * | 2022-11-29 | 2023-04-21 | 黑龙江飞鹤乳业有限公司 | Nutritional composition containing lactoferrin and probiotics, food and application |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL2004201C2 (en) * | 2010-02-05 | 2011-08-08 | Friesland Brands Bv | Use of sialyl oligosaccharides to modulate the immune system. |
US20160095339A1 (en) * | 2014-10-01 | 2016-04-07 | Mead Johnson Nutrition Company | Nutritional composition for gastrointestinal environment to provide improved microbiome and metabolic profile |
CN106820156A (en) * | 2017-02-17 | 2017-06-13 | 福建康是美生物科技有限公司 | A kind of probiotic composition of regulating intestinal canal flora health |
US20190029306A1 (en) * | 2016-01-26 | 2019-01-31 | Nestec S.A. | Composition for use in the prevention and/or treatment of skin conditions and skin diseases |
US20190060334A1 (en) * | 2016-01-26 | 2019-02-28 | Nestec S.A. | Compositions with specific oligosaccharides to prevent or treat allergies |
CN109430666A (en) * | 2018-10-15 | 2019-03-08 | 威海养经堂医药科技有限公司 | A kind of Freeze-dry Powder of Probioctics solid beverage |
-
2021
- 2021-06-15 CN CN202110665006.0A patent/CN113491337A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL2004201C2 (en) * | 2010-02-05 | 2011-08-08 | Friesland Brands Bv | Use of sialyl oligosaccharides to modulate the immune system. |
US20160095339A1 (en) * | 2014-10-01 | 2016-04-07 | Mead Johnson Nutrition Company | Nutritional composition for gastrointestinal environment to provide improved microbiome and metabolic profile |
US20190029306A1 (en) * | 2016-01-26 | 2019-01-31 | Nestec S.A. | Composition for use in the prevention and/or treatment of skin conditions and skin diseases |
US20190060334A1 (en) * | 2016-01-26 | 2019-02-28 | Nestec S.A. | Compositions with specific oligosaccharides to prevent or treat allergies |
CN106820156A (en) * | 2017-02-17 | 2017-06-13 | 福建康是美生物科技有限公司 | A kind of probiotic composition of regulating intestinal canal flora health |
CN109430666A (en) * | 2018-10-15 | 2019-03-08 | 威海养经堂医药科技有限公司 | A kind of Freeze-dry Powder of Probioctics solid beverage |
Non-Patent Citations (1)
Title |
---|
赵方舟,等: "早期乳铁蛋白干预对哺乳仔猪盲肠菌群结构、短链脂肪酸含量及黏膜炎症因子水平的影响", 南京农业大学学报 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115989836A (en) * | 2022-11-29 | 2023-04-21 | 黑龙江飞鹤乳业有限公司 | Nutritional composition containing lactoferrin and probiotics, food and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6985231B2 (en) | Use of purified 2'-fucosyllactoce, 3-fucosyllactose, and lactodifucotetraose as prebiotics | |
CN103384529B (en) | Be suitable for the method and composition controlling animal blood glucose | |
CN101188947B (en) | Use of polydextrose for simulating the functional attributes of human milk oligosaccharides in formula-fed infants | |
CN113475720B (en) | Application of osteopontin in increasing intestinal flora diversity and increasing intestinal short-chain fatty acid content | |
Noor et al. | Exploring the impact of the gut microbiome on obesity and weight loss: a review article | |
CN114558038B (en) | Probiotic composition for losing weight and reducing fat as well as preparation method and application thereof | |
AU2006244703B2 (en) | Method of improving immune function in mammals using 3-HPA producing lactobacillus strains in combination with medium chain triglyceride oil | |
Suh et al. | Inhibitory effect of galactooligosaccharide on skin pigmentation | |
MX2007012530A (en) | Use of lactobacillus rhamnosus gg for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant. | |
CN115068591B (en) | Probiotic composition containing osteopontin | |
CN113491337A (en) | Composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof | |
CN117731007A (en) | Pumpkin seed protein composition and application thereof | |
US20040105849A1 (en) | Treatment for SMA disease | |
Chaturvedi et al. | Human milk oligosaccharides: potential upshot on health at early life stage development | |
Chen et al. | A prebiotic formula improves the gastrointestinal bacterial flora in toddlers | |
CN112806577B (en) | Prebiotic probiotic synergistic combinations for butyric acid production | |
CN113966845A (en) | Nutritional composition for promoting intestinal health of infants | |
CN113476463A (en) | Prebiotic composition and application thereof | |
Gao et al. | Importance of gut microbiota in health and diseases of new born infants | |
YASMIN et al. | Effect of honey supplementation on plasma levels of short chain fatty acids in malnurished children | |
CN118633735A (en) | Application of the composition in preparing a product for improving constipation | |
KR102660139B1 (en) | Fermentation Products Comprising Short Chain Fatty Acids And Use Of Improving, Preventing Or Treating Overweight Thereof | |
CN112805010B (en) | Dietary fiber for treating patients with methylmalonic acidemia and propionic acidemia | |
Tyagi | 9. Role of prebiotics and probiotics in immunity | |
Miller | Update on the Gut Microbiome for the Primary Care Clinician. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211012 |
|
RJ01 | Rejection of invention patent application after publication |